دورية أكاديمية
أعرض في EDS

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.

التفاصيل البيبلوغرافية
العنوان: Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
المؤلفون: Loh HP; Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Mahfut FB; Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Chen SW; Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Huang Y; Singapore Immunology Network (SIGN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Huo J; Singapore Immunology Network (SIGN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Zhang W; Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore., Lam KP; Singapore Immunology Network (SIGN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Microbiology and Immunology, Singapore, Singapore., Xu S; Singapore Immunology Network (SIGN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.; Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Yang Y; Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
المصدر: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2231129.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101479829 Publication Model: Print Cited Medium: Internet ISSN: 1942-0870 (Electronic) Linking ISSN: 19420862 NLM ISO Abbreviation: MAbs Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: Antibodies, Bispecific* , Single-Chain Antibodies*, T-Lymphocytes ; Immunoglobulin Fab Fragments ; Immunoglobulin G
مستخلص: T-cell-engaging bispecific antibodies (T-bsAbs) are promising immunotherapies for cancer treatment due to their capability of redirecting T-cells toward destroying tumor cells. Numerous T-bsAb formats have been developed, each with advantages and disadvantages in terms of developability, immunogenicity, effector functions, and pharmacokinetics. Here, we systematically compared T-bsAbs produced using eight different formats, evaluating the effect of molecular design of T-bsAbs on their manufacturability and functionality. These eight T-bsAb formats were constructed using antigen-binding fragments (Fabs) and single-chain variable fragments (scFvs) of antibodies linked to the crystallizable fragment (Fc) domain of immunoglobulin G. To ensure a fair comparison of growth and production data, we used recombinase-mediated cassette exchange technology to generate the T-bsAb-producing CHO cell lines. The produced T-bsAbs were assessed for their purification profile and recovery, binding capability, and biological activities. Our findings indicated that the manufacturability of bsAbs was adversely affected with increased number of scFv building blocks, while the functionality was affected by the combination of multiple factors, including the binding affinity and avidity of targeting moieties and the flexibility and geometry of formats. These results provide valuable insights into the impact of the format design on the optimal production and function of T-bsAbs.
References: J Chromatogr A. 2019 Sep 13;1601:121-132. (PMID: 31056270)
Protein Sci. 2017 Oct;26(10):2021-2038. (PMID: 28726352)
J Biol Chem. 2010 Jun 18;285(25):19637-46. (PMID: 20400508)
MAbs. 2019 May/Jun;11(4):639-652. (PMID: 30698484)
Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. (PMID: 21690412)
Cancer Cell. 2017 Mar 13;31(3):383-395. (PMID: 28262555)
Lancet Oncol. 2022 Aug;23(8):1055-1065. (PMID: 35803286)
Protein Eng Des Sel. 2010 Apr;23(4):221-8. (PMID: 20019028)
Nat Rev Drug Discov. 2019 Aug;18(8):585-608. (PMID: 31175342)
BMC Biotechnol. 2016 Oct 18;16(1):71. (PMID: 27756290)
Front Immunol. 2021 May 05;12:626616. (PMID: 34025638)
J Pharm Sci. 2008 Apr;97(4):1414-26. (PMID: 17721938)
J Biol Chem. 2017 Sep 1;292(35):14706-14717. (PMID: 28655766)
Front Cell Dev Biol. 2020 Jan 10;7:370. (PMID: 31998721)
Antib Ther. 2022 Oct 13;5(4):288-300. (PMID: 36518226)
Br J Cancer. 2004 May 4;90(9):1863-70. (PMID: 15150594)
J Mol Biol. 2003 Jun 27;330(1):99-111. (PMID: 12818205)
Am J Pathol. 2013 Nov;183(5):1446-1460. (PMID: 24035511)
Clin Dev Immunol. 2012;2012:980250. (PMID: 22474489)
MAbs. 2015;7(1):231-42. (PMID: 25427258)
Antib Ther. 2022 Jun 09;5(2):138-149. (PMID: 35774245)
J Biol Chem. 2015 Mar 20;290(12):7535-62. (PMID: 25583986)
Blood. 2017 Feb 2;129(5):609-618. (PMID: 27908880)
J Hematol Oncol. 2015 Dec 21;8:130. (PMID: 26692321)
PLoS One. 2013 May 21;8(5):e63247. (PMID: 23704898)
Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. (PMID: 30918018)
Biophys J. 2000 Jan;78(1):394-404. (PMID: 10620303)
Drugs. 2022 Nov;82(16):1613-1619. (PMID: 36352205)
J Immunother Cancer. 2021 Sep;9(9):. (PMID: 34497115)
Cancer Immunol Immunother. 2010 Aug;59(8):1197-209. (PMID: 20309546)
PLoS One. 2012;7(12):e51817. (PMID: 23284778)
Methods. 2019 Feb 1;154:102-117. (PMID: 30395966)
J Biotechnol. 2012 Jan;157(1):130-9. (PMID: 22024589)
Sci Transl Med. 2018 Oct 17;10(463):. (PMID: 30333240)
AAPS J. 2006 Aug 04;8(3):E501-7. (PMID: 17025268)
Sci Rep. 2021 Jun 21;11(1):12969. (PMID: 34155258)
Biochem Biophys Res Commun. 2007 Apr 13;355(3):751-7. (PMID: 17321501)
Immunotherapy. 2021 Feb;13(2):125-141. (PMID: 33172323)
Hum Vaccin Immunother. 2019;15(3):594-602. (PMID: 30380973)
J Biol Chem. 2014 Jul 4;289(27):18693-706. (PMID: 24841203)
Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5467-E5476. (PMID: 29844189)
Clin Pharmacol. 2013 Apr 12;5(Suppl 1):5-11. (PMID: 23671399)
Pharmacol Ther. 2018 Feb;182:161-175. (PMID: 28834699)
Clin Cancer Res. 2016 Jul 1;22(13):3286-97. (PMID: 26861458)
Trends Pharmacol Sci. 2010 Feb;31(2):53-9. (PMID: 19963283)
Methods. 2019 Feb 1;154:77-86. (PMID: 30102989)
Nat Biotechnol. 2014 Feb;32(2):191-8. (PMID: 24463572)
Mol Immunol. 2015 Oct;67(2 Pt A):58-66. (PMID: 25883042)
Protein Cell. 2018 Jan;9(1):121-129. (PMID: 28585177)
Biotechnol J. 2017 Dec;12(12):. (PMID: 29090854)
Methods. 2019 Feb 1;154:10-20. (PMID: 30326272)
Comput Struct Biotechnol J. 2020 May 14;18:1221-1227. (PMID: 32542108)
Protein Eng. 1996 Jul;9(7):617-21. (PMID: 8844834)
Biochemistry. 1994 Nov 1;33(43):12746-51. (PMID: 7947678)
Science. 1985 Sep 6;229(4717):974-6. (PMID: 2992089)
Antib Ther. 2020 Feb 17;3(1):18-62. (PMID: 33928225)
Drug Discov Today. 2015 Jul;20(7):838-47. (PMID: 25728220)
Methods. 2019 Feb 1;154:70-76. (PMID: 30145356)
Oncoimmunology. 2016 May 05;5(6):e1168557. (PMID: 27471647)
Methods. 2019 Feb 1;154:38-50. (PMID: 30366098)
BioDrugs. 2018 Oct;32(5):441-464. (PMID: 30132211)
Biomol Eng. 2001 Jun;17(6):193-202. (PMID: 11337278)
MAbs. 2017 Feb/Mar;9(2):182-212. (PMID: 28071970)
Trends Biotechnol. 1991 Apr;9(4):132-7. (PMID: 1367550)
فهرسة مساهمة: Keywords: CHO cell; avidity; bispecific antibody; functionality; manufacturability; targeted integration; thermal stability
المشرفين على المادة: 0 (Antibodies, Bispecific)
0 (Immunoglobulin Fab Fragments)
0 (Immunoglobulin G)
0 (Single-Chain Antibodies)
تواريخ الأحداث: Date Created: 20230705 Date Completed: 20230706 Latest Revision: 20230718
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10324450
DOI: 10.1080/19420862.2023.2231129
PMID: 37403264
قاعدة البيانات: MEDLINE
الوصف
تدمد:1942-0870
DOI:10.1080/19420862.2023.2231129